Co-Diagnostics Inc (CODX) (Q3 2026) Earnings Call Highlights: Dual Regulatory Submissions ...
Co-Diagnostics Inc (CODX) reported ~97.3% sensitivity for its India TB test, filed a dual FDA submission for its Flu A/B and RSV assay, and cut operating expenses 12% while awaiting its first Related Stocks: CODX ,